Este	O
estudio	O
aleatorizado	O
,	O
multicéntrico	O
,	O
de	O
fase	O
III	O
comparó	O
doxorrubicina	O
y	O
docetaxel	O
(	O
AT	O
)	O
con	O
doxorrubicina	O
y	O
ciclofosfamida	O
(	O
AC	O
)	O
como	O
quimioterapia	O
de	O
primera	O
línea	O
(	O
CT	O
)	O
en	O
el	O
cáncer	O
de	O
mama	O
metastásico	O
(	O
CMM	O
)	O
.	O

Los	O
pacientes	O
(	O
n	O
=	O
429	O
)	O
fueron	O
asignados	O
al	O
azar	O
para	O
recibir	O
doxorrubicina	O
50	O
mg/m	O
(	O
2	O
)	O
más	O
docetaxel	O
75	O
mg/m	O
(	O
2	O
)	O
(	O
n	O
=	O
214	O
)	O
o	O
doxorrubicina	O
60	O
mg/m	O
(	O
2	O
)	O
más	O
ciclofosfamida	O
600	O
mg/m	O
(	O
2	O
)	O
)	O
(	O
n	O
=	O
215	O
)	O
el	O
día	O
1	O
,	O
cada	O
3	O
semanas	O
hasta	O
ocho	O
ciclos	O
.	O

El	O
tiempo	B-Premise-Support-7
hasta	I-Premise-Support-7
la	I-Premise-Support-7
progresión	I-Premise-Support-7
(	I-Premise-Support-7
TTP	I-Premise-Support-7
;	I-Premise-Support-7
punto	I-Premise-Support-7
final	I-Premise-Support-7
primario	I-Premise-Support-7
)	I-Premise-Support-7
y	I-Premise-Support-7
el	I-Premise-Support-7
tiempo	I-Premise-Support-7
hasta	I-Premise-Support-7
el	I-Premise-Support-7
fracaso	I-Premise-Support-7
del	I-Premise-Support-7
tratamiento	I-Premise-Support-7
(	I-Premise-Support-7
TTF	I-Premise-Support-7
)	I-Premise-Support-7
fueron	I-Premise-Support-7
significativamente	I-Premise-Support-7
más	I-Premise-Support-7
largos	I-Premise-Support-7
con	I-Premise-Support-7
AT	I-Premise-Support-7
que	I-Premise-Support-7
con	I-Premise-Support-7
AC	I-Premise-Support-7
(	I-Premise-Support-7
mediana	I-Premise-Support-7
de	I-Premise-Support-7
TTP	I-Premise-Support-7
,	I-Premise-Support-7
37,3	I-Premise-Support-7
frente	I-Premise-Support-7
a	I-Premise-Support-7
31,9	I-Premise-Support-7
semanas	I-Premise-Support-7
;	I-Premise-Support-7
rango	I-Premise-Support-7
logarítmico	I-Premise-Support-7
P	I-Premise-Support-7
=	I-Premise-Support-7
0,014	I-Premise-Support-7
,	I-Premise-Support-7
mediana	I-Premise-Support-7
de	I-Premise-Support-7
TTF	I-Premise-Support-7
,	I-Premise-Support-7
25,6	I-Premise-Support-7
frente	I-Premise-Support-7
a	I-Premise-Support-7
23,7	I-Premise-Support-7
semanas	I-Premise-Support-7
,	I-Premise-Support-7
rango	I-Premise-Support-7
logarítmico	I-Premise-Support-7
P	I-Premise-Support-7
=	I-Premise-Support-7
0,048	I-Premise-Support-7
)	I-Premise-Support-7
.	I-Premise-Support-7

La	B-Premise-Support-6
tasa	I-Premise-Support-6
de	I-Premise-Support-6
respuesta	I-Premise-Support-6
global	I-Premise-Support-6
(	I-Premise-Support-6
ORR	I-Premise-Support-6
)	I-Premise-Support-6
fue	I-Premise-Support-6
significativamente	I-Premise-Support-6
mayor	I-Premise-Support-6
para	I-Premise-Support-6
los	I-Premise-Support-6
pacientes	I-Premise-Support-6
que	I-Premise-Support-6
tomaban	I-Premise-Support-6
AT	I-Premise-Support-6
(	I-Premise-Support-6
59	I-Premise-Support-6
%	I-Premise-Support-6
,	I-Premise-Support-6
con	I-Premise-Support-6
10	I-Premise-Support-6
%	I-Premise-Support-6
de	I-Premise-Support-6
respuesta	I-Premise-Support-6
completa	I-Premise-Support-6
[	I-Premise-Support-6
CR	I-Premise-Support-6
]	I-Premise-Support-6
,	I-Premise-Support-6
49	I-Premise-Support-6
%	I-Premise-Support-6
de	I-Premise-Support-6
respuesta	I-Premise-Support-6
parcial	I-Premise-Support-6
[	I-Premise-Support-6
PR	I-Premise-Support-6
]	I-Premise-Support-6
)	I-Premise-Support-6
que	I-Premise-Support-6
para	I-Premise-Support-6
los	I-Premise-Support-6
que	I-Premise-Support-6
tomaban	I-Premise-Support-6
AC	I-Premise-Support-6
(	I-Premise-Support-6
47	I-Premise-Support-6
%	I-Premise-Support-6
,	I-Premise-Support-6
con	I-Premise-Support-6
7	I-Premise-Support-6
%	I-Premise-Support-6
de	I-Premise-Support-6
RC	I-Premise-Support-6
)	I-Premise-Support-6
.	I-Premise-Support-6
,	I-Premise-Support-6
39	I-Premise-Support-6
%	I-Premise-Support-6
RP	I-Premise-Support-6
)	I-Premise-Support-6
(	I-Premise-Support-6
p	I-Premise-Support-6
=	I-Premise-Support-6
0,009	I-Premise-Support-6
)	I-Premise-Support-6
.	I-Premise-Support-6

El	B-Premise-Support-5
ORR	I-Premise-Support-5
también	I-Premise-Support-5
fue	I-Premise-Support-5
mayor	I-Premise-Support-5
con	I-Premise-Support-5
AT	I-Premise-Support-5
en	I-Premise-Support-5
pacientes	I-Premise-Support-5
con	I-Premise-Support-5
compromiso	I-Premise-Support-5
visceral	I-Premise-Support-5
(	I-Premise-Support-5
58	I-Premise-Support-5
%	I-Premise-Support-5
vs	I-Premise-Support-5
41	I-Premise-Support-5
%	I-Premise-Support-5
;	I-Premise-Support-5
hígado	I-Premise-Support-5
,	I-Premise-Support-5
62	I-Premise-Support-5
%	I-Premise-Support-5
vs	I-Premise-Support-5
42	I-Premise-Support-5
%	I-Premise-Support-5
;	I-Premise-Support-5
pulmón	I-Premise-Support-5
,	I-Premise-Support-5
58	I-Premise-Support-5
%	I-Premise-Support-5
vs	I-Premise-Support-5
35	I-Premise-Support-5
%	I-Premise-Support-5
)	I-Premise-Support-5
,	I-Premise-Support-5
compromiso	I-Premise-Support-5
de	I-Premise-Support-5
tres	I-Premise-Support-5
o	I-Premise-Support-5
más	I-Premise-Support-5
órganos	I-Premise-Support-5
(	I-Premise-Support-5
59	I-Premise-Support-5
%	I-Premise-Support-5
vs	I-Premise-Support-5
.	I-Premise-Support-5
40	I-Premise-Support-5
%	I-Premise-Support-5
)	I-Premise-Support-5
,	I-Premise-Support-5
o	I-Premise-Support-5
CT	I-Premise-Support-5
adyuvante	I-Premise-Support-5
previo	I-Premise-Support-5
(	I-Premise-Support-5
53	I-Premise-Support-5
%	I-Premise-Support-5
vs	I-Premise-Support-5
41	I-Premise-Support-5
%	I-Premise-Support-5
)	I-Premise-Support-5
.	I-Premise-Support-5

La	B-Premise-Support-5
supervivencia	I-Premise-Support-5
general	I-Premise-Support-5
(	I-Premise-Support-5
SG	I-Premise-Support-5
)	I-Premise-Support-5
fue	I-Premise-Support-5
comparable	I-Premise-Support-5
en	I-Premise-Support-5
ambos	I-Premise-Support-5
brazos	I-Premise-Support-5
.	I-Premise-Support-5

La	O
neutropenia	B-Premise-Support-5
de	I-Premise-Support-5
grado	I-Premise-Support-5
3/4	I-Premise-Support-5
fue	I-Premise-Support-5
común	I-Premise-Support-5
en	I-Premise-Support-5
ambos	I-Premise-Support-5
grupos	I-Premise-Support-5
,	I-Premise-Support-5
aunque	B-Premise-Partial_Attack--1
la	I-Premise-Partial_Attack--1
neutropenia	I-Premise-Partial_Attack--1
febril	I-Premise-Partial_Attack--1
y	I-Premise-Partial_Attack--1
las	I-Premise-Partial_Attack--1
infecciones	I-Premise-Partial_Attack--1
fueron	I-Premise-Partial_Attack--1
más	I-Premise-Partial_Attack--1
comunes	I-Premise-Partial_Attack--1
en	I-Premise-Partial_Attack--1
los	I-Premise-Partial_Attack--1
pacientes	I-Premise-Partial_Attack--1
que	I-Premise-Partial_Attack--1
tomaban	I-Premise-Partial_Attack--1
AT	I-Premise-Partial_Attack--1
(	I-Premise-Partial_Attack--1
respectivamente	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
33	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
vs	I-Premise-Partial_Attack--1
.	I-Premise-Partial_Attack--1
10	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
P	I-Premise-Partial_Attack--1
<	I-Premise-Partial_Attack--1
0,001	I-Premise-Partial_Attack--1
;	I-Premise-Partial_Attack--1
8	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
vs	I-Premise-Partial_Attack--1
.	I-Premise-Partial_Attack--1
2	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
P=0,01	I-Premise-Partial_Attack--1
)	I-Premise-Partial_Attack--1
.	I-Premise-Partial_Attack--1

La	B-Premise
toxicidad	I-Premise
no	I-Premise
hematológica	I-Premise
grave	I-Premise
fue	I-Premise
rara	I-Premise
en	I-Premise
ambos	I-Premise
grupos	I-Premise
,	I-Premise
incluidos	I-Premise
los	I-Premise
eventos	I-Premise
cardíacos	I-Premise
de	I-Premise
grado	I-Premise
3/4	I-Premise
(	I-Premise
AT	I-Premise
,	I-Premise
3	I-Premise
%	I-Premise
;	I-Premise
AC	I-Premise
,	I-Premise
4	I-Premise
%	I-Premise
)	I-Premise
.	I-Premise

AT	B-Claim-Support-2
mejora	I-Claim-Support-2
significativamente	I-Claim-Support-2
la	I-Claim-Support-2
TTP	I-Claim-Support-2
y	I-Claim-Support-2
la	I-Claim-Support-2
ORR	I-Claim-Support-2
en	I-Claim-Support-2
comparación	I-Claim-Support-2
con	I-Claim-Support-2
AC	I-Claim-Support-2
en	I-Claim-Support-2
pacientes	I-Claim-Support-2
con	I-Claim-Support-2
CMM	I-Claim-Support-2
,	I-Claim-Support-2
pero	B-Claim-Partial_Attack--1
no	I-Claim-Partial_Attack--1
hay	I-Claim-Partial_Attack--1
diferencia	I-Claim-Partial_Attack--1
en	I-Claim-Partial_Attack--1
la	I-Claim-Partial_Attack--1
SG	I-Claim-Partial_Attack--1
.	I-Claim-Partial_Attack--1

AT	B-Claim
representa	I-Claim
una	I-Claim
opción	I-Claim
válida	I-Claim
para	I-Claim
el	I-Claim
tratamiento	I-Claim
de	I-Claim
MSCC	I-Claim
.	I-Claim

